To present a case of juvenile dermatomyositis (JDM) associated with acute myeloid leukemia (AML) and evaluate the outcomes following hematopoietic stem cell transplantation (HSCT), emphasizing its significance in pediatric oncology.
Key Findings:
JDM can progress to AML, though this is rare in pediatric cases, highlighting the need for vigilance in monitoring.
HSCT may provide a successful treatment option for patients with refractory autoimmune-hematologic malignancy overlap syndromes, suggesting a new avenue for therapy.
Sustained remission of both JDM and AML was observed after HSCT, indicating potential for long-term management.
Interpretation:
This case highlights the potential for HSCT to treat complex cases involving autoimmune disorders and hematologic malignancies, warranting further research to validate its efficacy and explore mechanisms.
Limitations:
This is a single case study; broader studies are needed to confirm findings and assess generalizability.
Long-term outcomes beyond one year post-HSCT are not reported, which limits understanding of durability of remission.
Conclusion:
HSCT may be a viable treatment for pediatric patients with concurrent JDM and AML, but further validation through larger studies is necessary, especially given the rarity of such cases.
